Anna Doubrovsky1, Scott W Menzies. 1. Sydney Melanoma Unit, Melanoma and Skin Cancer Research Institute, Department of Surgery, University of Sydney, Sydney, Australia. anna@mel.rpa.cs.nsw.gob.au
Abstract
OBJECTIVE: To calculate survival probabilities of patients with 3 or more multiple primary melanomas. DESIGN: Retrospective cohort study of patients with primary melanoma. SETTING: Patients treated at a tertiary center (Sydney Melanoma Unit, Sydney, Australia) for stage I or II melanoma between 1983 and 1999. Patients From 5250 patients with primary melanoma, 264 (5.0%) had double and 34 (0.6%) had 3 or more primary melanoma lesions. RESULTS: The estimated 10-year risk for developing a second primary melanoma in these patients was 12.7% (95% confidence interval [CI], 10.5%-14.9%). For those patients who had 2 primary melanomas, the estimated 10-year risk of developing a third lesion was 27.7% (95% CI, 14.7%-36.7%). When controlling for known prognostic factors in a proportional hazards regression model, the number of primary melanomas was a significant favorable survival predictor when the thickest or the first tumor was modeled. In patients with 3 or more primary melanomas, 31 survived when 25 (95% CI, 22-27) were expected to survive. Patients who survive longer may have the opportunity to develop multiple primary melanomas. Patients who encountered all their primary lesions within 2 years may not be subject to this bias. Within the 3 or more melanoma set, 11 patients had all primary melanomas within 2 years. All survived, whereas 9 (95% CI, 8-10) were expected to survive. CONCLUSIONS: Patients with 3 or more primary melanoma lesions survive longer than anticipated. Such enhanced survival in patients with 3 or more primary melanomas may be consistent with observations of an "immunization effect" in animals inoculated with multiple tumors.
OBJECTIVE: To calculate survival probabilities of patients with 3 or more multiple primary melanomas. DESIGN: Retrospective cohort study of patients with primary melanoma. SETTING:Patients treated at a tertiary center (Sydney Melanoma Unit, Sydney, Australia) for stage I or II melanoma between 1983 and 1999. Patients From 5250 patients with primary melanoma, 264 (5.0%) had double and 34 (0.6%) had 3 or more primary melanoma lesions. RESULTS: The estimated 10-year risk for developing a second primary melanoma in these patients was 12.7% (95% confidence interval [CI], 10.5%-14.9%). For those patients who had 2 primary melanomas, the estimated 10-year risk of developing a third lesion was 27.7% (95% CI, 14.7%-36.7%). When controlling for known prognostic factors in a proportional hazards regression model, the number of primary melanomas was a significant favorable survival predictor when the thickest or the first tumor was modeled. In patients with 3 or more primary melanomas, 31 survived when 25 (95% CI, 22-27) were expected to survive. Patients who survive longer may have the opportunity to develop multiple primary melanomas. Patients who encountered all their primary lesions within 2 years may not be subject to this bias. Within the 3 or more melanoma set, 11 patients had all primary melanomas within 2 years. All survived, whereas 9 (95% CI, 8-10) were expected to survive. CONCLUSIONS:Patients with 3 or more primary melanoma lesions survive longer than anticipated. Such enhanced survival in patients with 3 or more primary melanomas may be consistent with observations of an "immunization effect" in animals inoculated with multiple tumors.
Authors: Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong Journal: Ann Surg Oncol Date: 2011-09-13 Impact factor: 5.344
Authors: Maris S Jones; Hitoe Torisu-Itakura; Devin C Flaherty; Hans F Schoellhammer; Jihey Lee; Myung-Shim Sim; Mark B Faries Journal: Am Surg Date: 2016-10 Impact factor: 0.688
Authors: Nadine A Kasparian; Shab Mireskandari; Phyllis N Butow; Mbathio Dieng; Anne E Cust; Bettina Meiser; Kristine Barlow-Stewart; Scott Menzies; Graham J Mann Journal: Support Care Cancer Date: 2016-07-27 Impact factor: 3.603
Authors: A E Cust; C Badcock; J Smith; N E Thomas; L E Haydu; B K Armstrong; M H Law; J F Thompson; P A Kanetsky; C B Begg; Y Shi; A Kricker; I Orlow; A Sharma; S Yoo; S F Leong; M Berwick; D W Ollila; S Lo Journal: Br J Dermatol Date: 2019-11-27 Impact factor: 9.302
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Nancy E Thomas; Lynn From; Klaus Busam; Peter A Kanetsky; Richard P Gallagher; Loraine D Marrett; Pamela A Groben; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Terence Dwyer; Marianne Berwick Journal: JAMA Dermatol Date: 2013-08 Impact factor: 10.282
Authors: Lucie Rychetnik; Rachael L Morton; Kirsten McCaffery; John F Thompson; Scott W Menzies; Les Irwig Journal: BMC Health Serv Res Date: 2012-12-19 Impact factor: 2.655
Authors: Adi Nosrati; Wesley Y Yu; Joseph McGuire; Ann Griffin; Juliana Rocha de Souza; Rasnik Singh; Eleni Linos; Mary Margaret Chren; Barbara Grimes; Nicholas P Jewell; Maria L Wei Journal: J Invest Dermatol Date: 2018-07-19 Impact factor: 7.590